DrugPatentWatch Database Preview

Incyte Corp Company Profile

« Back to Dashboard

What is the competitive landscape for INCYTE CORP, and when can generic versions of INCYTE CORP drugs launch?

INCYTE CORP has one approved drug.

There are seven US patents protecting INCYTE CORP drugs.

There are one hundred and forty-nine patent family members on INCYTE CORP drugs in forty-one countries and twenty supplementary protection certificates in thirteen countries.

Summary for Incyte Corp

International Patents:	149
US Patents:	7
Tradenames:	1
Ingredients:	1
NDAs:	1

Drugs and US Patents for Incyte Corp

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-003	Nov 16, 2011		RX	Yes	No	9,662,335			Y
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-003	Nov 16, 2011		RX	Yes	No	7,598,257		Y	Y
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-004	Nov 16, 2011		RX	Yes	No	8,822,481
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-002	Nov 16, 2011		RX	Yes	No	8,822,481

Paragraph IV (Patent) Challenges for INCYTE CORP drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	5 mg, 10 mg, 15 mg, 20 mg, and 25 mg		2015-12-17

Non-Orange Book US Patents for Incyte Corp

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,933,086	Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors
8,946,245	Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
9,206,187	Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase
8,530,485	Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors

International Patents for Incyte Corp Drugs

Country	Document Number	Estimated Expiration
Cuba	23933
Portugal	2173752
Hong Kong	1198652
Ecuador	SP12008540

Supplementary Protection Certificates for Incyte Corp Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2017012	Lithuania		PRODUCT NAME: RUKSOLITINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/12/773/001-006 20150311
2013000015	Germany		PRODUCT NAME: RUXOLITINIB ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/12/773/001-003 20120823
2013 00005	Denmark		PRODUCT NAME: RUXOLITINIB, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER RUXOLITINIB PHOSFAT; REG. NO/DATE: EU/1/12/773/001-003 20120823
2017 00018	Denmark		PRODUCT NAME: RUXOLITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER RUXOLITINIB FOSFAT; REG. NO/DATE: C(2015)1740/EU/1/12/773/001-016 20150313

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Incyte Corp